



**GlaxoSmithKline
Supplier Diversity
5 Moore Drive
PO Box 13398
Durham, NC 27709-3398**

Tel. 919.315.3781
Fax: 336.369.8974
www.gsk.com

VIA ELECTRONIC MAIL (AGO.highcostprescriptiondrugs@vermont.gov)

June 19, 2019

Office of The Attorney General
State of Vermont
Attn: TJ Donovan, Attorney General
109 State Street
Montpelier, VT 05609

RE: Notice of New Prescription Drug Pursuant to 18 V.S.A §4637(b)

Dear Mr. Donovan:

GlaxoSmithKline ("GSK") is issuing this notice pursuant to 18 V.S.A §4637(b) to inform you that on June 17, 2019 GSK introduced two new prescription drugs to market (in the U.S. and Vermont) at a wholesale acquisition price above the threshold set for a specialty drug under the Medicare Part D program.

The two new drugs, listed below with their respective NDCs, are:

- (1) NUCALA, NUCALA INJ 100MG/ML (NDC:00173089201); and
- (2) NUCALA, NUCALA INJ 100MG/ML (NDC:00173089242)

Please let me know if you have any questions about this notice or the products referenced herein.

Yours very truly,

Nick Vigliarolo
Director, Strategic Pricing
Payer Marketing
US

Email Nick.A.Vigliarolo@gsk.com